VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Koo on Degarelix for the Treatment of Prostate Cancer

Alec S. Koo, MD
Published: Tuesday, Nov 24, 2015



Alec S. Koo, MD, FACS, managing partner, Skyline Urology, board of directors, Large Urology Group Practice Association (LUGPA), discusses degarelix (Firmagon) for the treatment of patients with prostate cancer.

Degarelix is an LHRH antagonist that, both functionally and theoretically, has advantages over agonists. It also suppresses testosterone levels quicker and more efficiently, Koo explains.

Usually, when patients begin on agonists, an initial flare occurs and testosterone levels take longer to drop, Koo says. Degarelix should be administered when patients first start on LHRH therapy.


Alec S. Koo, MD, FACS, managing partner, Skyline Urology, board of directors, Large Urology Group Practice Association (LUGPA), discusses degarelix (Firmagon) for the treatment of patients with prostate cancer.

Degarelix is an LHRH antagonist that, both functionally and theoretically, has advantages over agonists. It also suppresses testosterone levels quicker and more efficiently, Koo explains.

Usually, when patients begin on agonists, an initial flare occurs and testosterone levels take longer to drop, Koo says. Degarelix should be administered when patients first start on LHRH therapy.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x